Eli Lilly and Company Breaks Ground on $6.5 Billion Houston Manufacturing Site

Eli Lilly is investing $6.5B in a Houston manufacturing facility, aiming to boost production of its oral GLP-1 treatment, Foundayo. The project highlights challenges in forecasting demand for breakthrough therapeutics and underscores Houston's growing role as a biomanufacturing hub. The investment is part of a broader trend of U.S. pharma reshoring.

The XBI biotech ETF has surged 25% this year and 80% over 12 months, driven by big pharma acquisitions to offset patent expirations. Key deals include Vertex's $10B acquisition of Crinetics and Eli Lilly's $3.8B deal for AtaiBeckley. Potential targets include Viking Therapeutics and Sellas Life Sciences. Retail sentiment is extremely bearish, with XBI at a record-low score of 21.

Eli Lilly (LLY) broke ground on a $6.5B Houston facility to manufacture active pharmaceutical ingredients, including Foundayo (orforglipron), a GLP-1 drug for weight management. The site, part of Lilly's $50B U.S. investment, will create 600+ jobs and is supported by a $12.5M workforce training initiative with San Jacinto College. Foundayo is under regulatory review in over 40 countries, with global rollout targeted for 2027.

Eli Lilly began construction on a $6.5B Houston facility to manufacture its GLP-1 pill and other medicines, creating over 600 jobs. The company also invested $12.5M in San Jacinto College for workforce training. This is part of Lilly's $50B push to reshore medicine production. Foundayo, a synthetic oral GLP-1 medicine, will be produced at the facility.

Eli Lilly began construction on a $6.5B Houston factory, set to open in 2030. The site will produce Foundayo, a synthetic oral GLP-1 medication, and other therapeutics. The project is part of Lilly's $50B U.S. investment, creating 4,000 construction jobs and hundreds of permanent roles. Lilly also committed $15M to San Jacinto College for workforce development.

The FDA approved Eli Lilly's imlunestrant (Inluriyo) with abemaciclib (Verzenio) for ESR1-mutated breast cancer after disease progression. Guardant360 Liquid CDx was approved to detect the mutation. AstraZeneca's rival combo, camizestrant (Etcamah) with CDK4/6 inhibitors, was approved earlier. Lilly's approval was based on EMBER-3 trial data showing improved progression-free survival with the combination.